CHRONIC MYELOGENOUS LEUKEMIA: A REVIEW AND UPDATE OF CURRENT AND FUTURE THERAPY
Journal Title: International Journal of Pharmacy and Pharmaceutical Sciences - Year 2016, Vol 8, Issue 7
Abstract
Leukemia is a cancer of marrow and blood, which is a clonal myeloproliferative disease, characterized by the presence of oncogenic Philadelphia chromosome, formed by a reciprocal translocation between chromosomes 9 and 22, resulting in the novel chimeric oncoprotein BCR/ABL. Chronic leukemia typically progresses slowly and permits the growth of greater numbers of more developed cells. If the cell change takes place in a type of marrow cell that normally goes on to form red blood cells, some kinds of white blood cells and platelets, the leukemia is called “myeloid. Therapy for chronic myeloid leukemia depends on the stage of CML patient. After diagnosis and confirmation of CML positive patient, treatment available for patients includes imatinib that is an early diagnosed treatment for CML but after some duration of time, it may lead to resistance to imatinib treatment. Dasatinib, nilotinib, bosutinib & ponatinib can be used for the treatment of CML as secondary treatments. Ponatinib is also found effective against T315i mutation patients. Omacetaxine mepesuccinate can be given with a mechanism of action independent of tyrosine kinase inhibition. Clinical trial for development of advanced therapy, which includes combination therapy and newer developed a treatment against CML are going on. It is required to develop better drug therapy, which will not cause genetical mutation and drug resistant. It is also required to find out thecause of resistance and what are the possible ways by which better therapy for CML is possible.Keywords: Philadelphia (Ph) chromosome, chronic myeloid leukemia, Imatinib, Tyrosine Kinase Inhibitor (TKI), Haematological Response (HR), Cytogenetic Response (CR), Molecular Responses (MR), Reverse Transcriptase Polymerase Chain Reaction (RTPCR), BCR-ABL gene, T315I mutation, Imatinib-Resistance
Authors and Affiliations
Ankit Ashokkumar Darji, Praful D Bharadia
Keywords
Related Articles
- EP ID EP576206
- DOI -
- Views 53
- Downloads 0
QUALITY OF LIFE OF CHRONIC KIDNEY DISEASE PATIENTS WITH ROUTINE HEMODIALYSIS IN GENERAL HOSPITALS IN SLEMAN YOGYAKARTA
Objective: To elicit quality of life (QOL) of chronic kidney disease (CKD) patients with routine hemodialysis receiving erythropoietin, to compare the QOL of CKD patients with routine hemodialysis receiving different ery...
NANO-SPONGE NOVEL DRUG DELIVERY SYSTEM AS CARRIER OF ANTI-HYPERTENSIVE DRUG
Objective: The study was designed to prepare Nano-sponge formulation loaded with nifedipine. Studying parameters which affecting the formulas in addition to pharmacokinetics and toxicity tests. Methods: Nine Nano-sponge...
IN VITRO SUSCEPTIBILITY OF ISOLATED SHIGELLA FLEXNERI AND SHIGELLA DYSENTERIAE TO THE ETHANOLIC EXTRACTS OF TRACHYSPERMUM AMMI AND PEGANUM HARMALA
Objective: This study represents the first attempt to investigate the antimicrobial activity of Peganum harmala, and Trachyspermum ammi seeds extract against the isolated bacillary dysentery-causing microorganisms. Meth...
PREVALENT RISK FACTORS OF HCV TRANSMISSION IN HEALTH CARE WORKERS (HCWS) IN PAKISTAN
Objective: To study and analyze the prevalent risk factors of Hepatitis C Virus (HCV) transmission in Health Care Workers (HCWs) in PakistanMethods: A literature survey (2005-2012) was conducted from the available litera...
ASSESSMENT OF ANTIFUNGAL ACTIVITY OF CASSIA FISTULA L. FRUIT PULP AGAINST ALTERNARIA SOLANI
In the present study antifungal activity of crude and partially purified extracts of Cassia fistula L. fruit pulp has been assayed against Alternaria solani which is responsible for early blight of potato. Cold and hot e...